
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : 1315 Capital
Deal Size : Undisclosed
Deal Type : Financing
USpharma Ltd. Secures Growth Capital Investment by 1315 Capital
Details : The capital infusion will enable USpharma to accelerate the development and commercialization of its pipeline, including Milnacipran tablets reference product of Savella.
Product Name : Savella-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2025
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : 1315 Capital
Deal Size : Undisclosed
Deal Type : Financing
